A Frontline Respiratory Tool for COVID-19 Patients
Trusted Frontline Respiratory Support
High flow nasal cannula is an internationally recommended respiratory tool for COVID-19 patients, with recommendations and guidance from healthcare organizations around the world, including:
- World Health Organization
- Centers for Disease Control
- Society for Critical Care Management
- American College of Emergency Physicians
- Associazione Italiana Pneumologi Ospedalieri
- Chinese Thoracic Society
Fast Disinfection and Workflow Streamlining
- Start delivering heated, humidified therapy in minutes.
- The single use disposable patient circuits can be used up to 30 days, then discarded.
- The Precision Flow System can be disinfected in less than 10 minutes.
- Nurse call and EMR integration, as well as a large, easily read LED display allow hospitals options in bedside monitoring.
Want to learn more about Vapotherm high velocity therapy?
More than High Flow Nasal Cannula
More than twenty years ago, Vapotherm invented high flow nasal cannula. Today, Vapotherm high velocity therapy is an advanced form of high flow nasal cannula, capable of providing ventilatory support clinically proven non-inferior to NiPPV – without the need for a tight-fitting respiratory mask.
One device can allow hospitals readiness for a broad range of patient acuity, from supporting the oxygenation and humidification needs of COVID-19 patients, to hypercapnic COPD patients. 
Best Practices for Vapotherm High Velocity Therapy for COVID-19 Patients
With the application of a simple surgical mask, particulate spread is similar to that of normal patient breathing. After applying the cannula to the patient, fit a surgical mask, then initiate therapy.
On-demand Webinar: COVID-19 Patients on High Velocity Nasal Insufflation – Considerations & Transmission Protection
Presented By: John Walsh, CRT
- Review COVID-19 symptoms
- Review COVID-19 transmission risks
- Discuss HVNI in the context of COVID-19 management
- Overview the proper protective measures to reduce transmission risk during HVNI
This course is AARC accredited for 1 CEU under the Clinical Practice (CLP) category
COVID-19 Clinical Resources
Looking for more clinical information? Our COVID-19 Resource Center is regularly updated.
SOURCES:  Doshi, Pratik et al. High-Velocity Nasal Insufflation in the Treatment of Respiratory Failure: A Randomized Clinical Trial. Annals of Emergency Medicine, 2018. Published online ahead of print. https://www.ncbi.nlm.nih.gov/pubmed/29310868